1. Home
  2. TGTX vs FRHC Comparison

TGTX vs FRHC Comparison

Compare TGTX & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$53.27

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Logo Freedom Holding Corp.

FRHC

Freedom Holding Corp.

SELL

Current Price

$173.49

Market Cap

10.3B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
TGTX
FRHC
Founded
1993
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
10.3B
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
TGTX
FRHC
Price
$53.27
$173.49
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $69.71
N/A
AVG Volume (30 Days)
★ 1.5M
57.0K
Earning Date
11-02-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1746.67
79.29
EPS
0.17
★ 0.52
Revenue
$2,785,000.00
★ $2,191,291,000.00
Revenue This Year
$55.81
N/A
Revenue Next Year
$37.36
N/A
P/E Ratio
★ $305.97
$335.06
Revenue Growth
N/A
★ 6.86
52 Week Low
$26.76
$107.98
52 Week High
$59.30
$178.00

Technical Indicators

Market Signals
Indicator
TGTX
FRHC
Relative Strength Index (RSI) 44.82 57.92
Support Level $51.76 $136.38
Resistance Level $58.26 $175.47
Average True Range (ATR) 2.18 5.37
MACD -0.55 0.04
Stochastic Oscillator 27.90 74.84

Price Performance

Historical Comparison
TGTX
FRHC

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About FRHC Freedom Holding Corp.

Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.

Share on Social Networks: